We are currently developing biomarkers that serve different functions:
Lin, W.M., Baker, A.C., Beroukhim, R., Winkler, W., Feng, W., Marmion, J., Laine, E., Greulich, H., Tseng, H., Gates, C., Hodi, F.S., Dranoff, G. M., Sellers, W. R., Thomas, R. K., Meyerson, M., Golub, T. R., Dummer, R., Herlyn, M., Getz, G., Garraway, L.A.: Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 68: 664-673, 2008. PMID18245465
Hoek, K.S., Schlegel, N. C., Brafford, P., Sucker, A., Ugurel, S., Kumar, R., Weber, B. L., Nathanson, K. L., Phillips, D. J., Herlyn, M., Schadendorf, D., Dummer, R.: Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pig. Cell Res. 19: 290-302, 2006. PMID16827748
Han, M.-J., Herlyn, M., Fisher, A.B. Speicher, D. W.: Microscale solution IEF combined with 2-D DIGE substantially enhances analysis depth of complex proteomes such as mammalian cell and tissue extracts. Electrophoresis 29: 695-705, 2008. PMID18186533
Spittle, C., Ward, M.R., Nathanson, K.L., Gimotty, P.A., Rappaport, E., Brose, M.S.., Medina, A., Letrero, R., Herlyn, M., Edwards, R.H.: Application of a BRAF Pyrosequencing Assay for Mutation Detection and Copy Number Analysis in Malignant Melanoma. J. Molec. Diagn. 9: 464-471, 2007. PMID17690212
Thomas, R.K., Baker, A.C., Debiasi, R.M., Winckler, W., Laframboise, T., Lin, W.M., Wang, M., Feng, W., Zander, T., Macconnaill, L.E., Lee, J.C., Nicoletti, R., Hatton, C., Goyette. M., Girard, L., Majmudar, K., Ziaugra, L., Wong, K.K., Gabriel, S., Beroukhim, R., Peyton, M., Barretina, J., Dutt, A., Emery, C., Greulich, H., Shah, K., Sasaki, H., Gazdar, A., Minna, J., Armstrong, S.A., Mellinghoff, I.K., Hodi, F.S., Dranoff, G., Mischel, P.S., Cloughesy, T.F., Nelson, S.F., Liau, L.M., Mertz, K., Rubin, M.A., Moch, H., Loda, M., Catalona, W., Fletcher, J., Signoretti, S., Kaye, F., Anderson, K.C., Demetri, G.D., Dummer, R., Wagner, S., Herlyn, M., Sellers, W.R., Meyerson, M., Garraway, L.,A.: High-throughput oncogene mutation profiling in human cancer. Nature Genet. 39: 347-351, 2007 PMID 17293865. Corrigendum: 39: 567, 2007. PMID 17392811
Smalley, K.S., Contractor, R., Haass, N.K., Lee, J.T., Nathanson, K.L., Medina, C.A., Flaherty, K.T., Herlyn, M.: Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Brit. J. Cancer 96: 445-449, 2007. PMID 1721070